Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation

International Journal of Cancer

Volumn 132, Issue 5, 2013, Pages 1013-1021

  Frazzi, Raffaele ^a   Valli, Riccardo ^a   Tamagnini, Ione ^a   Casali, Bruno ^a   Latruffe, Norbert ^b   Merli, Francesco ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b Faculté des Sciences Gabriel   (France)

Author keywords

germinal center B lymphocytes; Hodgkin lymphoma; resveratrol; SIRT1

Indexed keywords

CASPASE 3; HISTONE DEACETYLASE; LYSINE; PROTEIN BAX; PROTEIN P53; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR FKHRL1;

ACETYLATION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REED STERNBERG CELL;

ACETYLATION; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FORKHEAD TRANSCRIPTION FACTORS; GERMINAL CENTER; HODGKIN DISEASE; HUMANS; LYMPH NODES; S PHASE; SIRTUIN 1; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872865080     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27748     Document Type: Article

References (43)

1. Gosslau A, Li S, Ho CT, et al. The importance of natural product characterization in studies of their anti-inflammatory activity. Mol Nutr Food Res 2011; 55: 74-82.
2. Galleano M, Pechanova O, Fraga CG,. Hypertension, nitric oxide, oxidants, and dietary plant polyphenols. Curr Pharm Biotechnol 2010; 11: 837-48.
3. Magrone T, Jirillo E,. Polyphenols from red wine are potent modulators of innate and adaptive immune responsiveness. Proc Nutr Soc 2010; 69: 279-85.
4. Colin DJS, Jacquet A, Lizard G, et al. Resveratrol accumulates into lipid rafts to cancer cells by endocytosis. Cancer Prevent Res 2011; 4: 1095-106.
5. Colin DGA, Lizard G, Izard J-C, et al. Resveratrol analogues compounds induced early S phase arrest through specific Cdk/cyclin complex which leads to a higher sensitization of human colon cancer cells to 5-FU. Int J Cancer 2009; 124: 2780-8.
6. Delmas D, Passilly-Degrace P, Jannin B, et al. Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. Int J Mol Med 2002; 10: 193-9.
7. Tyihak E, Kiraly-Veghely Z, Moricz AM,. Multiple beneficial effects of resveratrol and their chemical-biochemical basis. Nat Prod Commun 2011; 6: 631-8.
8. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
9. Pocernich CB, Lange ML, Sultana R, et al. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr Alzheimer Res 2011; 8: 452-69.
10. Shadfar S, Couch ME, McKinney KA, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer 2011; 63: 749-62.
11. Baile CA, Yang JY, Rayalam S, et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci 2011; 1215: 40-7.
12. Salado C, Olaso E, Gallot N, et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med 2011; 9: 59.
13. Shi Y, Yang S, Troup S, et al. Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep 2011; 25: 1713-9.
14. Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009; 486: 95-102.
15. Delmas DLA, Colin D, Jannin B, et al. Resveratrol as chemopreventive agent: new concepts to put forward the molecule to fight cancer. Curr Drug Target 2006; 7: 423-42.
16. Shimizu T, Nakazato T, Xian MJ, et al. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem Pharmacol 2006; 71: 742-50.
17. Faber AC, Dufort FJ, Blair D, et al. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol 2006; 72: 1246-56.
18. Guha P, Dey A, Sen R, et al. Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther 2011; 336: 206-14.
19. Punnett A, Tsang RW, Hodgson DC,. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol 2010; 20: 30-44.
20. Howlader NNA, Krapcho M, Neyman N, et al., eds. SEER Cancer Statistics Review, 1975-2008: National Cancer Institute, Bethesda, MD. SEER website, 2011.
21. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437-48.
22. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-77.
23. Esteller M,. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-98.
24. Nosho K, Shima K, Irahara N, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009; 22: 922-32.
25. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-5.
26. Motta MCDN, Lemieux M, Kamel C, et al., Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
27. Luo J, Altieri DC,. SIRTing through breast cancer is just a survivin' game. Mol Cell 2008; 32: 159-60.
28. Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 2011; 90: 538-45.
29. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 2008; 32: 11-20.
30. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612-8.
31. Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32: 1523-31.
32. Ubezio P,. Microcomputer experience in analysis of flow cytometric DNA distributions. Comput Programs Biomed 1985: 159-66.
33. Boatright KM, Salvesen GS,. Mechanisms of caspase activation. Curr Opin Cell Biol 2003; 15: 725-31.
34. Liu TLP, Marshall G,. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009: 1702-05.
35. Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285: 8340-51.
36. Stunkel W, Campbell RM,. Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen 2011; 16: 1153-69.
37. Gatto D, Brink R,. The germinal center reaction. J Allergy Clin Immunol 2010; 126: 898-907; quiz 8-9.
38. Jaffe ES, Vardiman JW, Campo E, et al. Hematopathology. In: Elsevier. ed., 2011. 100-6.
39. Kuppers R,. Molecular biology of Hodgkin lymphoma. Hematology 2009: 491-96.
40. Subramanian L, Youssef S, Bhattacharya S, et al. Resveratrol: challenges in translation to the clinic-a critical discussion. Clin Cancer Res 2010; 16: 5942-8.
41. Patel KR, Scott E, Brown VA, et al. Clinical trials of resveratrol. Ann NY Acad Sci 2011; 1215: 161-9.
42. Yun JM, Chien A, Jialal I, et al. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 2012; 23: 699-705.
43. Baarine MTS, Louis XL, Mazué F, et al. Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells. Genes Nutr 2011; 2: 161-9.